The initiation of coverage by RBC Capital with an Outperform rating and a specific price target of $12 is a strong positive signal for Applied Therapeutics. This kind of analyst coverage often leads to increased investor interest and can drive the stock price up in the short term, especially if the market perceives the analysis as credible and well-founded.